Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Antihypertensive Treatment With β-Blockade in Patients With Asymptomatic Aortic Stenosis and Association With Cardiovascular Events

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Prognosis and Reclassification by YKL-40 in Stable Coronary Artery Disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Potassium Disturbances and Risk of Ventricular Fibrillation Among Patients With ST-Segment-Elevation Myocardial Infarction

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Neonatal Risk in Children of Women With Congenital Heart Disease: A Cohort Study With Focus on Socioeconomic Status

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Cardiovascular Manifestations of Systemic Sclerosis: A Danish Nationwide Cohort Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. New-onset of postoperative atrial fibrillation is likely to recur in the absence of other triggers

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Early Gadolinium Enhancement for Determination of Area at Risk: A Preclinical Validation Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Casper N Bang
  • Anders M Greve
  • Anne B Rossebø
  • Simon Ray
  • Kenneth Egstrup
  • Kurt Boman
  • Christoph Nienaber
  • Peter M Okin
  • Richard B Devereux
  • Kristian Wachtell
Vis graf over relationer

BACKGROUND: Patients with aortic stenosis (AS) often have concomitant hypertension. Antihypertensive treatment with a β-blocker (Bbl) is frequently avoided because of fear of depression of left ventricular function. However, it remains unclear whether antihypertensive treatment with a Bbl is associated with increased risk of cardiovascular events in patients with asymptomatic mild to moderate AS.

METHODS AND RESULTS: We did a post hoc analysis of 1873 asymptomatic patients with mild to moderate AS and preserved left ventricular ejection fraction in the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) study. Propensity-matched Cox regression and competing risk analyses were used to assess risk ratios for all-cause mortality, sudden cardiac death, and cardiovascular death. A total of 932 (50%) patients received Bbl at baseline. During a median follow-up of 4.3±0.9 years, 545 underwent aortic valve replacement, and 205 died; of those, 101 were cardiovascular deaths, including 40 sudden cardiovascular deaths. In adjusted analyses, Bbl use was associated with lower risk of all-cause mortality (hazard ratio 0.5, 95% confidence interval 0.3-0.7, P<0.001), cardiovascular death (hazard ratio 0.4, 95% confidence interval 0.2-0.7, P<0.001), and sudden cardiac death (hazard ratio 0.2, 95% confidence interval 0.1-0.6, P=0.004). This was confirmed in competing risk analyses (all P<0.004). No interaction was detected with AS severity (all P>0.1).

CONCLUSIONS: In post hoc analyses Bbl therapy did not increase the risk of all-cause mortality, sudden cardiac death, or cardiovascular death in patients with asymptomatic mild to moderate AS. A prospective study may be warranted to determine if Bbl therapy is in fact beneficial.

CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00092677.

OriginalsprogEngelsk
TidsskriftJournal of the American Heart Association
Vol/bind6
Udgave nummer12
Sider (fra-til)e006709
ISSN2047-9980
DOI
StatusUdgivet - 27 nov. 2017

ID: 52213530